



(43) International Publication Date
1 October 2009 (01.10.2009)

PCT

(10) International Publication Number
WO 2009/121039 A2

(51) International Patent Classification:

A61K 31/5513 (2006.01) A61K 47/10 (2006.01)
A61K 31/355 (2006.01) A61P 25/22 (2006.01)
A61K 9/16 (2006.01)

(21) International Application Number:

PCT/US2009/038696

(22) International Filing Date:

27 March 2009 (27.03.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/040,558 28 March 2008 (28.03.2008) US

(71) Applicant (for all designated States except US):

HALE BIOPHARMA VENTURES, LLC [US/US]; 1042-B N. El Camino Real, Suite 430, Encinitas, CA 92024 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only):

CARTT, Steve [US/US]; 3260 Whipple Road, Union City, CA 94587 (US). **MEDEIROS, David** [US/US]; 212 Crown Circle, South San Francisco, CA 94080 (US). **GWOZDZ, Garry, Thomas** [US/US]; 329 South Main Street, Nazareth, PA 18064 (US). **LOXLEY, Andrew** [GB/US]; 126 Market Street, #5, Philadelphia, PA 18064 (US). **MITCHNICK, Mark** [US/US]; 80 Three Mile Harbor Drive, East Hampton, NY 11937 (US). **HALE, David** [US/US]; 1042-b N. El Camino Real, Suite 430, Encinitas, CA 92024 (US).

(74) Agents:

AKHAVAN, Ramin et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))



WO 2009/121039 A2

(54) Title: ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS

(57) Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal ad-

ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS

[001] This application claims priority under 35 U.S.C. § 119(e) from United States provisional patent application number 61/040,558, which was filed on March 28, 2008, and which is incorporated
5 herein in its entirety.

FIELD OF THE INVENTION

[002] This application relates to the nasal administration of benzodiazepine drugs and combinations thereof.

BACKGROUND OF THE INVENTION

10 [003] By way of non-limiting example, the benzodiazepine family consists of drugs such as diazepam, lorazepam, and medazepam. The drugs in this family have been observed as possessing sedative, tranquilizing and muscle relaxing properties. They are frequently classified as an anxiolytic and skeletal muscle relaxants. They are thought to be useful in preventing, treating, or ameliorating the symptoms of anxiety, insomnia, agitation, seizures (such as those caused by epilepsy), muscle
15 spasms and rigidity (which can be caused by tetanus), the symptoms of drug withdrawal associated with the continuous abuse of central nervous system depressants, and exposure to nerve agents.

[004] Benzodiazepines are thought to act by binding to the GABA_A receptor of a neuron, possibly causing the receptor to change shape and making it more accessible to gamma-aminobutyric acid (GABA).

20 [005] GABA is an inhibitory neurotransmitter that, when bound to the GABA_A receptor, facilitates Cl⁻ ions flooding into the neuron to which the receptor is bound. The increase in Cl⁻ ions hyperpolarizes the membrane of the neuron. This completely or substantially reduces the ability of the neuron to carry an action potential. Targeting this receptor is particularly useful in treating many disorders, such as tetanus and epilepsy, which may result from too many action potentials proceeding
25 through the nervous system.

[006] Current formulations of benzodiazepine drugs can be administered orally, rectally, or parenterally. The ability to utilize these and other types of formulations has been significantly limited due, in many cases, to solubility challenges.

[007] The oral route of administration may be considered sub-optimal due to several disadvantages.
30 For example, the amount of time required for an orally administered benzodiazepine drug to reach therapeutically relevant concentrations in blood plasma may be rather long, such as an hour or more. Moreover, as benzodiazepine drugs pass through the liver a significant amount may be metabolized. Thus, it may require large doses to achieve therapeutic plasma levels. Furthermore, due to the nature

of seizures and muscle spasms, it can be extremely difficult for either a patient or a care-giver to administer the benzodiazepine drug orally.

[008] Intravenous administration perhaps provides a faster route of administration. However intravenous administration is generally limited to trained health care professionals in tightly controlled clinical settings. Additionally, sterility must be maintained. Furthermore, administering any drug intravenously can be painful and is likely impractical for patients suffering from a phobia of needles.

[009] Suppository compositions of benzodiazepine drugs can have a rapid onset of action. However, the inconvenience of suppositories is an obvious impediment to their being administered by anyone outside a very small group of the patient's intimate acquaintances and the patient's professional medical caretakers.

SUMMARY OF THE INVENTION

[010] In some embodiments, the pharmaceutical composition for nasal administration comprises: a benzodiazepine drug; one or more natural or synthetic tocopherols or tocotrienols, or any combinations thereof, in an amount from about 30% to about 95% (w/w); and one or more alcohols or glycols, or any combinations thereof, in an amount from about 5% to about 70% (w/w), preferably about 10% to about 70% (w/w) in a pharmaceutically-acceptable formulation for administration to one or more nasal mucosal membranes of the patient. In some embodiments the benzodiazepine drug is dissolved in the one or more natural or synthetic tocopherols or tocotrienols, or any combinations thereof, in an amount from about 30% to about 95% (w/w); and the one or more alcohols or glycols, or any combinations thereof, in an amount from about 5% to about 70% (w/w), preferably about 10% to about 70% (w/w). In some embodiments, the benzodiazepine drug is dissolved in a carrier system. In some embodiments, at least part of the benzodiazepine drug is in a form comprising benzodiazepine microparticles, nanoparticles or combinations thereof. In some embodiments, the composition is substantially free of benzodiazepine microparticles, nanoparticles or combinations thereof.

[011] In some embodiments, the benzodiazepine drug is selected from the group consisting of: alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, diazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam, oxazepam, medazepam, lorazepam, prazepam, quazepam, triazolam, temazepam, loprazolam, any pharmaceutically-acceptable salts thereof, and any combinations thereof. In some embodiments, the benzodiazepine drug is diazepam, or a pharmaceutically-acceptable salt thereof. In some embodiments, the benzodiazepine drug comprises benzodiazepine microparticles, nanoparticles, or combinations thereof. In some embodiments, the benzodiazepine nanoparticles have an effective average particle size of less than about 5000 nm. In some embodiments, the benzodiazepine drug is substantially free of benzodiazepine microparticles, nanoparticles or combinations thereof.

[012] In some embodiments, the one or more natural or synthetic tocopherols or tocotrienols are selected from the group consisting of: α -tocopherol, β -tocopherol, γ -tocopherol, δ -tocopherol, α -tocotrienol, β -tocotrienol, γ -tocotrienol, δ -tocotrienol, tocophersolan, any isomers thereof, any esters thereof, any analogs or derivatives thereof, and any combinations thereof. In some embodiments, a synthetic tocopherol can include Vitamin E TPGS (Vitamin E polyethylene glycol succinate). In some embodiments, on the other hand, synthetic tocopherols exclude tocopherols covalently bonded or linked (e.g. through a diacid linking group) to a glycol polymer, such as polyethylene glycol). Thus, in some embodiments, the compositions described herein exclude Vitamin E TPGS.

[013] In some embodiments, one or more alcohols are selected from the group consisting of: ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl alcohol, any isomers thereof, or any combinations thereof. In some embodiments, the one or more glycols are selected from the group consisting of: ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, any isomers thereof, and any combinations thereof. In some preferred embodiments, the glycols exclude glycol polymers. In some preferred embodiments, the glycols exclude glycol polymers having an average molecular weight of greater than 200. In some embodiments, the glycols exclude polyethylene glycol having an average molecular weight of greater than about 200.

[014] In some embodiments, the benzodiazepine drug is present in the carrier system in a concentration from about 1 mg/mL to about 600 mg/mL. In some embodiments, the benzodiazepine drug is present in a carrier system in a concentration from about 10 mg/mL to about 250 mg/mL. In some embodiments, the benzodiazepine is present in a carrier system in a concentration from about 20 mg/mL to about 50 mg/mL.

[015] In some embodiments, the carrier system comprises one or more natural or synthetic tocopherols or tocotrienols, or any combinations thereof, in an amount from about 45% to about 85% (w/w). In some embodiments, the carrier system comprises one or more natural or synthetic tocopherols or tocotrienols, or any combinations thereof, in an amount from about 60% to about 75% (w/w). In some embodiments, the carrier system comprises one or more natural or synthetic tocopherols or tocotrienols, or any combinations thereof, in an amount of about 70% (w/w).

[016] In some embodiments, the carrier system comprises one or more alcohols or glycols, or any combinations thereof, in an amount from about 10% to about 70% (w/w). In some embodiments, the carrier system comprises one or more alcohols or glycols, or any combinations thereof, in an amount from about 15% to about 55% (w/w). In some embodiments, the carrier system comprises one or more alcohols or glycols, or any combinations thereof, in an amount from about 25% to about 40% (w/w). In some embodiments, the carrier system comprises one or more alcohols or glycols, or any combinations thereof, in an amount of about 30% (w/w).

[017] In some embodiments, the composition comprises at least one additional ingredient selected from the group consisting of: active pharmaceutical ingredients; enhancers; excipients; and agents

used to adjust the pH, buffer the composition, prevent degradation, and improve appearance, odor, or taste.

[018] In some embodiments, the composition comprises one or more additional excipients, such as one or more parabens, one or more povidones, and/or one or more alkyl glycosides.

5 **[019]** The invention also discloses a method of treating a patient with a disorder that may be treatable with a benzodiazepine drug. In some embodiments, the patient is a human. In some
embodiments, the method comprises: administering to one or more nasal mucosal membranes of a
patient a pharmaceutical composition for nasal administration comprising a benzodiazepine drug; one
or more natural or synthetic tocopherols or tocotrienols, or any combinations thereof, in an amount
10 from about 30% to about 95% (w/w); and one or more alcohols or glycols, or any combinations
thereof, in an amount from about 5% to about 70%, preferably about 10% to about 70% (w/w). In
some embodiments, the benzodiazepine is dissolved in the one or more natural or synthetic
tocopherols or tocotrienols, or any combinations thereof, in an amount from about 30% to about 95%
(w/w); and the one or more alcohols or glycols, or any combinations thereof, in an amount from about
15 5% to about 70%, preferably about 10% to about 70% (w/w). In some embodiments, the
benzodiazepine drug is dissolved in a carrier system. In some embodiments, the benzodiazepine drug
includes benzodiazepine microparticles, nanoparticles, or combinations thereof. In some
embodiments, the composition is substantially free of benzodiazepine microparticles, nanoparticles or
combinations thereof.

20 **[020]** In some embodiments, the benzodiazepine drug is selected from the group consisting of:
alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam,
diazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam,
oxazepam, medazepam, lorazepam, prazepam, quazepam, triazolam, temazepam, loprazolam, or any
pharmaceutically-acceptable salts thereof, and any combinations thereof. In some embodiments, the
25 benzodiazepine drug is diazepam, or a pharmaceutically-acceptable salt thereof. In some
embodiments, the benzodiazepine drug is fully dissolved in a single phase comprising one or more
one or more natural or synthetic tocopherols or tocotrienols and one or more alcohols or glycols. In
some embodiments, the benzodiazepine drug comprises benzodiazepine microparticles, nanoparticles,
or combinations thereof. In some such embodiments, the composition further comprises water. In
30 some embodiments, the benzodiazepine nanoparticles have an effective average particle size of less
than about 5000 nm. In some embodiments, the composition is substantially free of benzodiazepine
microparticles, nanoparticles or combinations thereof.

[021] In some embodiments, the one or more natural or synthetic tocopherols or tocotrienols are
selected from the group consisting of: α -tocopherol, β -tocopherol, γ -tocopherol, δ -tocopherol, α -
35 tocotrienol, β -tocotrienol, γ -tocotrienol, δ -tocotrienol, tocopherolsolan, any isomers thereof, any esters
thereof, any analogs or derivatives thereof, and any combinations thereof.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.